These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 18511928)

  • 1. Drug development of MET inhibitors: targeting oncogene addiction and expedience.
    Comoglio PM; Giordano S; Trusolino L
    Nat Rev Drug Discov; 2008 Jun; 7(6):504-16. PubMed ID: 18511928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
    Christensen JG; Burrows J; Salgia R
    Cancer Lett; 2005 Jul; 225(1):1-26. PubMed ID: 15922853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular cancer therapy: can our expectation be MET?
    Migliore C; Giordano S
    Eur J Cancer; 2008 Mar; 44(5):641-51. PubMed ID: 18295476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the MET oncogene in cancer and metastases.
    Stella GM; Benvenuti S; Comoglio PM
    Expert Opin Investig Drugs; 2010 Nov; 19(11):1381-94. PubMed ID: 20868306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
    Eder JP; Vande Woude GF; Boerner SA; LoRusso PM
    Clin Cancer Res; 2009 Apr; 15(7):2207-14. PubMed ID: 19318488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4.
    Matsumoto K; Nakamura T; Sakai K; Nakamura T
    Proteomics; 2008 Aug; 8(16):3360-70. PubMed ID: 18646008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in cancer therapy targeting c-Met signaling pathway.
    Jung KH; Park BH; Hong SS
    Arch Pharm Res; 2012 Mar; 35(4):595-604. PubMed ID: 22553051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges.
    Liu X; Newton RC; Scherle PA
    Trends Mol Med; 2010 Jan; 16(1):37-45. PubMed ID: 20031486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small molecule c-Met kinase inhibitors: a review of recent patents.
    Porter J
    Expert Opin Ther Pat; 2010 Feb; 20(2):159-77. PubMed ID: 20100000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer.
    Toschi L; Jänne PA
    Clin Cancer Res; 2008 Oct; 14(19):5941-6. PubMed ID: 18829470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy.
    Weinstein IB; Joe AK
    Nat Clin Pract Oncol; 2006 Aug; 3(8):448-57. PubMed ID: 16894390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase.
    Albrecht BK; Harmange JC; Bauer D; Berry L; Bode C; Boezio AA; Chen A; Choquette D; Dussault I; Fridrich C; Hirai S; Hoffman D; Larrow JF; Kaplan-Lefko P; Lin J; Lohman J; Long AM; Moriguchi J; O'Connor A; Potashman MH; Reese M; Rex K; Siegmund A; Shah K; Shimanovich R; Springer SK; Teffera Y; Yang Y; Zhang Y; Bellon SF
    J Med Chem; 2008 May; 51(10):2879-82. PubMed ID: 18426196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing biomarkers to predict benefit from HGF/MET pathway inhibitors.
    Koeppen H; Rost S; Yauch RL
    J Pathol; 2014 Jan; 232(2):210-8. PubMed ID: 24105670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of hepatocyte growth factor and the proto-oncogenic receptor c-Met in canine osteosarcoma.
    Fieten H; Spee B; Ijzer J; Kik MJ; Penning LC; Kirpensteijn J
    Vet Pathol; 2009 Sep; 46(5):869-77. PubMed ID: 19429984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MET receptor tyrosine kinase as a therapeutic anticancer target.
    Stellrecht CM; Gandhi V
    Cancer Lett; 2009 Jul; 280(1):1-14. PubMed ID: 19100682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. c-MET kinase inhibitors: a patent review (2011 - 2013).
    Zhu K; Kong X; Zhao D; Liang Z; Luo C
    Expert Opin Ther Pat; 2014 Feb; 24(2):217-30. PubMed ID: 24266843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathway.
    Tiran Z; Oren A; Hermesh C; Rotman G; Levine Z; Amitai H; Handelsman T; Beiman M; Chen A; Landesman-Milo D; Dassa L; Peres Y; Koifman C; Glezer S; Vidal-Finkelstein R; Bahat K; Pergam T; Israel C; Horev J; Tsarfaty I; Ayalon-Soffer M
    Clin Cancer Res; 2008 Jul; 14(14):4612-21. PubMed ID: 18628476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma.
    De Maria R; Miretti S; Iussich S; Olivero M; Morello E; Bertotti A; Christensen JG; Biolatti B; Levine RA; Buracco P; Di Renzo MF
    J Pathol; 2009 Jul; 218(3):399-408. PubMed ID: 19402129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new Met inhibitory-scaffold identified by a focused forward chemical biological screen.
    Patané S; Pietrancosta N; Hassani H; Leroux V; Maigret B; Kraus JL; Dono R; Maina F
    Biochem Biophys Res Commun; 2008 Oct; 375(2):184-9. PubMed ID: 18703015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma.
    Finisguerra V; Prenen H; Mazzone M
    Oncogene; 2016 Oct; 35(42):5457-5467. PubMed ID: 26996670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.